Tremelimumab is one of a number of immuno-oncology products that AstraZeneca is banking on as it focuses heavily on promising new treatments for cancer. The British drugmaker said on Wednesday its antibody treatment had been awarded the orphan designation, which aims to encourage drug development for rare conditions, by the U.S. Food and Drug Administration.
